Pfizer Reveals Their Coronavirus Vaccine Is 95% Effective After Completing Third Study Trial

A new report from Pfizer has come out of their coronavirus vaccine trials about the success rate of the vaccine they have been developing to help eradicate the pandemic.

The company has submitted a request to the Food and Drug Administration for emergency approval, as data for their vaccine has proven 95 percent effective.

Just a few weeks earlier, the company, along with collaborator BioNTech, announced that preliminary results from trials showed its potential vaccine was at least 90 percent effective.

Now, after completing a phase three study, the vaccine has proven to be 95 percent effective with “no serious safety concerns observed” in the trial participants.

“Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally,” Dr. Albert Bourla, Pfizer chairman and CEO, said in a news release. “Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential.”

The trials, Pfizer noted, have been “consistent across age, gender, race and ethnicity demographics” and “the observed efficacy in adults over 65 years of age was over 94 percent.”

“That’s great, but we have to get people to take the vaccine,” Dr. Anthony Fauci, who has been at the forefront of the fight against the virus in the United States, recently shared with press about the trials.

He also spoke about just when things could possibly be back to “normal”. Here’s what he said here…

Pfizer isn’t the only company to have had success with a vaccine for coronavirus. Moderna also reported a 95% success rate in early studies for their own vaccine.

Have you heard about this new effective treatment for coronavirus?